预约演示
更新于：2025-04-14
Ruxolitinib Phosphate
磷酸芦可替尼
更新于：2025-04-14
概要
基本信息
药物类型 小分子化药 |
别名 Jakabi、RUX、ruxolitinib (as phosphate) + [12] |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-11-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、加速审评 (欧盟)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C17H21N6O4P |
InChIKeyJFMWPOCYMYGEDM-XFULWGLBSA-N |
CAS号1092939-17-7 |
关联
444
项与 磷酸芦可替尼 相关的临床试验NCT06824103
A Single-arm Multi-center Study of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft Versus Host Disease After Allogeneic Stem Cell Transplantation
NCT06804811
A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06859424
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients with Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
100 项与 磷酸芦可替尼 相关的临床结果
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的转化医学
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的专利（医药）
登录后查看更多信息
3,387
项与 磷酸芦可替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial
Article
作者: Lai, Zhihong ; Cotliar, Jonathan ; Kuo, YuTzu ; Chiesa Fuxench, Zelma C. ; Nawaz, Haq
PURPOSE:
Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).
MATERIALS AND METHODS:
Patients aged 12-70 years with AD (Investigator's Global Assessment [IGA] score 2/3, ≤20% affected body surface area [face/neck, ≥0.5%]) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 4 weeks; thereafter, all patients applied as-needed ruxolitinib cream for 4 additional weeks. The primary endpoint was ≥75% improvement in head/neck Eczema Area and Severity Index (EASI-75) at Week 4 assessed by blinded central reader using photographs.
RESULTS:
Among 77 randomized patients (median [range] age, 38.0 [17-66] y), 44.2% were Black. The mean (SD) baseline head/neck EASI was 1.2 (0.7). More patients who applied ruxolitinib cream vs vehicle achieved head/neck EASI-75 at Week 4 (37.0% vs 17.4%; p = 0.091). Improvements with ruxolitinib cream vs vehicle were observed for facial/neck IGA treatment success (IGA 0/1 with ≥2-point improvement from baseline) and Patient-Oriented Eczema Measure (overall and itch). Ruxolitinib cream was well tolerated, including on the face and neck. Application site reactions were infrequent (ruxolitinib cream, 1.9% [n = 1]; vehicle, 8.7% [n = 2]).
CONCLUSIONS:
Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated.
2025-12-01Blood Research
Reversibility of acrocyanosis and improvement of capillaroscopic pattern in a patient with polycythemia vera treated with ruxolitinib: a case report
Article
作者: Nigro, Angelo
Abstract:
This case report describes the clinical course of a 78-year-old patient diagnosed with polycythemia vera (PV), who presented with pronounced acrocyanosis of the hands in 2021. The patient was treated with hydroxyurea (oncocarbide), and nailfold capillaroscopy revealed an “abnormal pattern” characterized by pronounced architectural disarray and capillary tortuosity, which is uncommon in patients with myeloproliferative neoplasms (MPNs). In 2023, owing to suboptimal symptom management and hematological side effects, the treatment was switched to ruxolitinib, which led to significant clinical improvements by 2024, including near-complete resolution of acrocyanosis and substantial improvement in capillaroscopic abnormalities, with only residual capillary tortuosity noted. This case emphasizes the need for individualized therapeutic interventions for PV, and underscores the potential role of ruxolitinib in ameliorating microvascular dysfunction.
2025-05-01Clinical Lymphoma Myeloma & Leukemia
A Review of Real-World Experience With Ruxolitinib for Myelofibrosis
Review
作者: Grunwald, Michael R ; Gerds, Aaron T ; Al-Ali, Haifa Kathrin ; Yu, Jingbo
Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by progressive bone marrow fibrosis and splenomegaly. Ruxolitinib is the standard-of-care first-line treatment option for MF. This review summarizes real-world effectiveness and safety of ruxolitinib in more than 4500 patients with MF from real-world settings, including expanded-access and phase 4 trials, as well as registry, postmarketing, and retrospective studies in the 10 years since regulatory approval. Consistent with results from the phase 3 COMFORT trials, real-world evidence supports the effectiveness of ruxolitinib in improving splenomegaly and MF symptoms while significantly increasing overall survival. Real-world safety data have also been aligned with results from the COMFORT trials. Transient anemia, thrombocytopenia, and infections are the most frequently observed adverse events (AEs) but rarely required ruxolitinib discontinuation. Other nonhematologic AEs are generally mild, and grade ≥ 3 events rarely occur. Importantly, real-world evidence also supports the effectiveness of ruxolitinib in patient groups that were poorly represented in clinical trials, including those with lower-risk MF, those presenting with thrombocytopenia or anemia, and those who have previously discontinued ruxolitinib treatment. Finally, cost-effectiveness analyses show ruxolitinib to be cost-effective in Europe and North America. Taken together, real-world studies reinforce the efficacy, safety, and cost-effectiveness of ruxolitinib for the treatment of patients with MF, supporting results from prospective clinical trials. Furthermore, they demonstrate the clinical benefit of ruxolitinib in patient subgroups poorly represented in clinical trials and the value of dose modifications or re-treatment after interruptions to optimize outcomes.
100 项与 磷酸芦可替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非节段型白癜风 | 美国 | 2022-07-18 | |
| 特应性皮炎 | 美国 | 2021-09-21 | |
| 原发性血小板增多症 | 中国 | 2017-03-10 | |
| 急性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 急性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 急性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 急性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 欧盟 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 冰岛 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 列支敦士登 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 挪威 | 2012-08-23 | |
| 真性红细胞增多症后骨髓纤维化 | 欧盟 | 2012-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度特应性皮炎 | 临床3期 | 美国 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 澳大利亚 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 比利时 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 保加利亚 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 加拿大 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 法国 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 德国 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 匈牙利 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 意大利 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 荷兰 | 2024-04-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 77 | 願齋淵餘齋蓋網醖鑰願(網鏇顧積構衊顧選壓鹹) = 積遞蓋糧繭夢廠選窪鹹 壓餘願齋鑰壓積窪築構 (醖遞網遞網簾壓鬱鬱窪 ) | 积极 | 2025-12-31 | ||
Vehicle cream | 願齋淵餘齋蓋網醖鑰願(網鏇顧積構衊顧選壓鹹) = 鹹窪醖遞襯壓觸鹽淵鑰 壓餘願齋鑰壓積窪築構 (醖遞網遞網簾壓鬱鬱窪 ) | ||||||
临床3期 | 674 | 餘積淵簾鑰顧積鏇憲築(膚網範壓築獵醖鬱鏇鹽) = Treatment-emergent AEs occurred in 52.1% (332/637) of patients 襯顧艱餘膚襯廠鑰衊網 (鏇構窪構顧簾蓋願憲蓋 ) 更多 | 积极 | 2025-03-29 | |||
Vehicle Cream | |||||||
临床2期 | 191 | (Navitoclax + Ruxolitinib (Cohort 1a)) | 壓製憲築襯壓遞襯鑰餘 = 簾鹽觸顧遞積積憲襯衊 網淵獵窪齋夢選鬱構廠 (醖襯鹽窪齋構積顧鏇齋, 鬱蓋窪鏇鏇艱艱顧構壓 ~ 蓋壓網觸範顧膚廠簾製) 更多 | - | 2025-03-12 | ||
(Navitoclax + Ruxolitinib (Cohort 1b)) | 壓製憲築襯壓遞襯鑰餘 = 鹽膚顧壓網夢蓋鑰衊鏇 網淵獵窪齋夢選鬱構廠 (醖襯鹽窪齋構積顧鏇齋, 遞鬱繭蓋艱鑰廠範製憲 ~ 觸積餘醖憲網憲築淵鑰) 更多 | ||||||
临床2期 | 55 | (Ruxolitinib 1.5% Cream BID) | 夢鏇膚製膚壓憲衊範憲(鏇齋憲觸構遞糧窪糧築) = 製糧顧遞範構憲積壓獵 顧顧積鑰衊膚襯夢壓網 (繭糧構製製膚鏇遞鹹製, 2.163) 更多 | - | 2025-02-20 | ||
(Ruxolitinib 1.5% Cream BID + NB-UVB) | 夢鏇膚製膚壓憲衊範憲(鏇齋憲觸構遞糧窪糧築) = 夢鏇範齋選觸鹹膚齋膚 顧顧積鑰衊膚襯夢壓網 (繭糧構製製膚鏇遞鹹製, 2.103) 更多 | ||||||
临床3期 | 29 | Ruxolitinib cream 1.5% | 觸壓選壓築簾襯蓋網獵(觸顧選淵艱鑰廠淵選醖) = 蓋窪鏇製鏇壓衊膚鑰鬱 齋艱窪選築簾淵鬱鹽憲 (壓膚鏇範糧鏇餘壓築繭 ) | 积极 | 2025-01-06 | ||
临床2期 | 3 | 餘鏇齋鑰顧艱築蓋壓襯 = 憲鹽夢廠膚襯廠糧觸築 製範築廠積選鹽築築衊 (憲遞築顧衊膚遞繭觸膚, 顧餘繭鹽顧淵蓋獵襯選 ~ 憲窪糧顧範艱糧鬱淵鹽) 更多 | - | 2024-12-27 | |||
临床2期 | 6 | 餘餘鹽夢鑰構齋淵壓簾 = 憲鹹鹹壓鏇夢願醖範壓 壓膚糧積夢襯繭選齋窪 (糧鑰獵獵鏇齋壓廠鬱網, 積鹽鬱夢艱鏇獵襯遞憲 ~ 範襯願鬱顧淵襯膚範構) 更多 | - | 2024-12-18 | |||
ASH2024 人工标引  | 临床2期 | 40 | 夢範網襯夢艱積衊鏇鬱(鏇鏇蓋憲鏇範蓋蓋齋鬱) = 簾糧觸範齋醖鹽襯鬱鏇 選觸壓鬱積醖餘艱餘糧 (艱憲襯鬱憲窪鑰膚鏇選 ) 更多 | 积极 | 2024-12-09 | ||
临床1期 | 13 | 醖襯鏇鬱鑰遞憲鑰鹽遞(積齋鑰醖窪膚壓襯鏇願) = None 積構鑰積鏇築襯夢網餘 (願壓選鹽醖製範觸窪範 ) 更多 | 积极 | 2024-12-09 | |||
N/A | - | 齋構夢簾淵鑰積蓋觸觸(窪獵獵簾壓鹽遞遞繭夢) = 齋憲憲築構壓獵構遞廠 衊膚鏇衊餘憲築醖鏇襯 (壓廠糧簾願膚廠齋顧齋, 1.1) 更多 | - | 2024-12-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用